Health Care • Biotechnology: Pharmaceutical Preparations
$43.13 ▲ +0.89
(+2.11%)
MKT CAP: $105.19B • VOL: 4.27M
52W L $39 52W H $53
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$36
MEDIAN
$48
MEAN
$49
HIGH
$59
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SNY TAPE
SNY // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $52.19 | $49.60 | 2025-02-14 | $39.25 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $54.34 | $50.89 | 2025-02-06 | $40.54 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $49.17 | $47.44 | 2025-01-29 | $41.40 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $43.99 | — | 2025-01-17 | $42.27 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $37.95 | $40.97 | 2025-01-09 | $38.39 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $51.32 | $44.86 | 2024-12-18 | $37.52 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $41.84 | $43.56 | 2024-12-04 | $40.11 | -4.3% | 48% | C |